Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (47)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity

    Biomedicine and Pharmacotherapy, Vol. 169

  3. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  4. Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates

    Brain : a journal of neurology, Vol. 146, Núm. 12, pp. 5000-5014

  5. Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors

    Frontiers in Immunology, Vol. 14

  6. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  2. Multi-omics signatures of the human early life exposome

    Nature Communications, Vol. 13, Núm. 1

2021

  1. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria

    Redox Biology, Vol. 46

  2. Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

  3. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

2020

  1. 2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

    Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257

2019

  1. SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer

    EBioMedicine, Vol. 40, pp. 406-421

2018

  1. Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

    Neurotherapeutics, Vol. 15, Núm. 4, pp. 1063-1081

  2. Gene therapy approaches in the non-human primate model of Parkinson’s disease

    Journal of Neural Transmission, Vol. 125, Núm. 3, pp. 575-589

  3. Glucocerebrosidase expression patterns in the non-human primate brain

    Brain Structure and Function, Vol. 223, Núm. 1, pp. 343-355

  4. Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification

    Atherosclerosis, Vol. 278, pp. 124-134

  5. Paracrine and Intracrine Angiotensin 1-7/Mas Receptor Axis in the Substantia Nigra of Rodents, Monkeys, and Humans

    Molecular Neurobiology, Vol. 55, Núm. 7, pp. 5847-5867